L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression

BACKGROUND: The repression or downregulation of programmed death-ligand 1 (PD-L1) can release its inhibition of T cells and activate antitumor immune responses. Although PD-1 and PD-L1 antibodies are promising treatments for diverse tumor types, their inherent disadvantages and immune-related advers...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jing, Wang, Xiaobo, Li, Bing, Shen, Shiyu, Wang, Ruina, Tao, Hongru, Hu, Junchi, Yu, Jin, Jiang, Hualiang, Chen, Kaixian, Luo, Cheng, Dang, Yongjun, Zhang, Yuanyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214382/
https://www.ncbi.nlm.nih.gov/pubmed/35728870
http://dx.doi.org/10.1136/jitc-2021-003957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214382/
https://www.ncbi.nlm.nih.gov/pubmed/35728870
http://dx.doi.org/10.1136/jitc-2021-003957

Ejemplares similares